Literature DB >> 20023420

Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells.

Shensi Shen1, Oliver Kepp, Isabelle Martins, Ilio Vitale, Sylvie Souquère, Maria Castedo, Gérard Pierron, Guido Kroemer.   

Abstract

Autophagy is commonly characterized by the redistribution of the microtubule-associated light chain 3 (LC3) protein into cytoplasmic puncta, coinciding with its lipidation, as well as by a decrease in the abundance of autophagic substrates including p62 and ubiquitinylated proteins. Here, we describe a cell line, A549-B480, which, in contrast to its parental A549 line, exhibits massive accumulation of LC3 (or a GFP-LC3 fusion protein) in cytoplasmic puncta. These puncta co-localize with accumulated p62 and ubiquitinylated proteins, yet are not enwrapped by membranes. Indeed, LC3 is not lipidated in A549-B480, even when these cells are cultured in conditions in which A549 cells would develop autophagy. A549-B480 cells have been selected for their resistance against the microtubule-stabilizing agent epothilone B and actually require the continuous presence of epothilone B for their survival. Parental A549 cells treated with epothilone B manifested all signs of bona fide autophagy. In contrast, the autophagic program of A549-B480 was defective, irrespective of the absence or presence of epothilone B, and correlated with the complete absence of Atg7, a protein that is reputed to be essential for autophagy. These results establish novel functional links between microtubules and autophagy, identify a new chemotherapy resistance-associated autophagic defect, and describe the existence of LC3 puncta outside from autophagosomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20023420     DOI: 10.4161/cc.9.2.10468

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  11 in total

Review 1.  Autophagy as a therapeutic target in cardiovascular disease.

Authors:  Andriy Nemchenko; Mario Chiong; Aslan Turer; Sergio Lavandero; Joseph A Hill
Journal:  J Mol Cell Cardiol       Date:  2011-06-23       Impact factor: 5.000

2.  The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.

Authors:  Christoph Oehler; André O von Bueren; Polina Furmanova; Angela Broggini-Tenzer; Katrin Orlowski; Stefan Rutkowski; Karl Frei; Michael A Grotzer; Martin Pruschy
Journal:  Neuro Oncol       Date:  2011-07-09       Impact factor: 12.300

3.  Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells.

Authors:  Ning Wang; Weidong Pan; Meifen Zhu; Maosheng Zhang; Xiaojian Hao; Guangyi Liang; Yibin Feng
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 4.  Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases.

Authors:  Alex Zhavoronkov; Zeljka Smit-McBride; Kieran J Guinan; Maria Litovchenko; Alexey Moskalev
Journal:  J Mol Med (Berl)       Date:  2012-10-23       Impact factor: 4.599

5.  Kaempferol induces autophagic cell death via IRE1-JNK-CHOP pathway and inhibition of G9a in gastric cancer cells.

Authors:  Tae Woo Kim; Seon Young Lee; Mia Kim; Chunhoo Cheon; Seong-Gyu Ko
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

Review 6.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 7.  Advances in targeting signal transduction pathways.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Lin Sun; Nicole M Davis; Stephen L Abrams; Richard A Franklin; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli; Massimo Libra; Saverio Candido; Giovanni Ligresti; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Marco Donia; Ferdinando Nicoletti; Jerry Polesel; Renato Talamini; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Michele; Agostino Tafuri; Joanna Dulińska-Litewka; Piotr Laidler; Antonio B D'Assoro; Lyudmyla Drobot; Drobot Umezawa; Giuseppe Montalto; Melchiorre Cervello; Zoya N Demidenko
Journal:  Oncotarget       Date:  2012-12

Review 8.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10

Review 9.  Harnessing of Programmed Necrosis for Fighting against Cancers.

Authors:  Young Sik Cho; Seung Yeon Park
Journal:  Biomol Ther (Seoul)       Date:  2014-05       Impact factor: 4.634

Review 10.  Mitotic Poisons in Research and Medicine.

Authors:  Jan Škubník; Michal Jurášek; Tomáš Ruml; Silvie Rimpelová
Journal:  Molecules       Date:  2020-10-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.